Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harinder Gill

Showing results (61-70 of 108) with videos related to

Pageof 11
Sort By:
American Journal of Hematology|March 16, 2013
Unremitting pyrexia, pancytopenia, hepatosplenomegaly, and extreme hyperferritinemiaHarinder Gill, Shasha Liu, Alvin Ip, et al.
Experimental Hematology & Oncology|October 28, 2022
Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patientsLai Heng Lee, Pongwut Danchaivijitr, Noppacharn Uaprasert, et al.
International Journal of Molecular Sciences|May 14, 2022
Single-Nucleotide Variations, Insertions/Deletions and Copy Number Variations in Myelodysplastic Syndrome during Disease Progression Revealed by a Single-Cell DNA Sequencing PlatformPaul Lee, Rita Yim, Sin-Hang Fung, et al.
Annals of Palliative Medicine|October 11, 2021
Impact of enhanced haematology palliative care services in patients with myelodysplastic syndrome and acute myeloid leukaemia: study protocol for a randomized controlled trialKwok Ying Chan, Harinder Gill, Cho Wing Li, et al.
American Journal of Hematology|May 30, 2012
Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study GroupEric Tse, Harinder Gill, Florence Loong, et al.
Annals of Hematology|June 17, 2023
Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by droplet-digital polymerase chain reactionVivian W K Li, Rita Yim, Paul Lee, et al.
Future Oncology (London, England)|August 4, 2022
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemiaSrdan Verstovsek, Norio Komatsu, Harinder Gill, et al.
Hematology (Amsterdam, Netherlands)|June 23, 2020
Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world settingHarinder Gill, Garret M K Leung, Rita Yim, et al.
Journal of Medical Genetics|June 18, 2020
<i>SETD1B</i>-associated neurodevelopmental disorderAlexandra Roston, Dan Evans, Harinder Gill, et al.
International Journal of Molecular Sciences|May 28, 2022
Epigenetic Silencing of <i>PTEN</i> and Epi-Transcriptional Silencing of <i>MDM2</i> Underlied Progression to Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Treated with Hypomethylating AgentsPaul Lee, Rita Yim, Kai-Kei Miu, et al.
Pageof 11

Showing results (61-70 of 108) with videos related to

Sort By:
Pageof 11
American Journal of Hematology|March 16, 2013
Unremitting pyrexia, pancytopenia, hepatosplenomegaly, and extreme hyperferritinemiaHarinder Gill, Shasha Liu, Alvin Ip, et al.
Experimental Hematology & Oncology|October 28, 2022
Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patientsLai Heng Lee, Pongwut Danchaivijitr, Noppacharn Uaprasert, et al.
International Journal of Molecular Sciences|May 14, 2022
Single-Nucleotide Variations, Insertions/Deletions and Copy Number Variations in Myelodysplastic Syndrome during Disease Progression Revealed by a Single-Cell DNA Sequencing PlatformPaul Lee, Rita Yim, Sin-Hang Fung, et al.
Annals of Palliative Medicine|October 11, 2021
Impact of enhanced haematology palliative care services in patients with myelodysplastic syndrome and acute myeloid leukaemia: study protocol for a randomized controlled trialKwok Ying Chan, Harinder Gill, Cho Wing Li, et al.
American Journal of Hematology|May 30, 2012
Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study GroupEric Tse, Harinder Gill, Florence Loong, et al.
Annals of Hematology|June 17, 2023
Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by droplet-digital polymerase chain reactionVivian W K Li, Rita Yim, Paul Lee, et al.
Future Oncology (London, England)|August 4, 2022
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemiaSrdan Verstovsek, Norio Komatsu, Harinder Gill, et al.
Hematology (Amsterdam, Netherlands)|June 23, 2020
Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world settingHarinder Gill, Garret M K Leung, Rita Yim, et al.
Journal of Medical Genetics|June 18, 2020
<i>SETD1B</i>-associated neurodevelopmental disorderAlexandra Roston, Dan Evans, Harinder Gill, et al.
International Journal of Molecular Sciences|May 28, 2022
Epigenetic Silencing of <i>PTEN</i> and Epi-Transcriptional Silencing of <i>MDM2</i> Underlied Progression to Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Treated with Hypomethylating AgentsPaul Lee, Rita Yim, Kai-Kei Miu, et al.
Pageof 11